These findings suggest that under standard-of-care chemotherapy, p53 deficiency is associated with poorer survival outcomes in about half of the evaluated cancer types; exceptions were observed in brain cancers in which p53 deficiency is associated with improved survival. The gene discussed is TP53; the disease is hyperinsulinemic hypoglycemia, familial, 4.